Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating NEXAGON® for the Treatment of Persistent Corneal Epithelial Defect (PCED)
•• Complete epithelial recovery was achieved by 67% of subjects receiving NEXAGON, as opposed to 27% receiving Vehicle alone •• NEXAGON was well-tolerated demonstrating a...